CD19 Antibody (1D3) - Azide and BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-80633
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human, Mouse, Rat
Applications
CyTOF-ready, Flow (Cell Surface), Flow Cytometry, Immunoprecipitation, In vivo assay
Label
Unconjugated
Antibody Source
Monoclonal Rat IgG2a Kappa Clone # 1D3
Format
Azide and BSA Free
Concentration
1 mg/ml
Product Specifications
Immunogen
Mouse CD19 Transfected Cell Line
Clonality
Monoclonal
Host
Rat
Isotype
IgG2a Kappa
Scientific Data Images for CD19 Antibody (1D3) - Azide and BSA Free
Flow Cytometry: CD19 Antibody (1D3) - Azide and BSA Free [NBP2-80633]
Flow Cytometry: CD19 Antibody (1D3) - Azide and BSA Free [NBP2-80633] - Cell surface analysis of CD19 in BALB/c mouse splenocytes using 1 ug of this antibody. Green: isotype control; red: anti-CD19 PE. Image using the PE form of this antibody. Image from the standard format of this antibody.Flow (Cell Surface): CD19 Antibody (1D3) - Azide and BSA Free [NBP2-80633]
Flow (Cell Surface): CD19 Antibody (1D3) - Azide and BSA Free [NBP2-80633] - Analysis using the Allophycocyanin conjugate of NBP2-24965. Staining of CD19 in BALB/c mouse splenocytes using 1 ug of this antibody. Green represents isotype control; red represents anti-CD19 APC.Flow Cytometry: CD19 Antibody (1D3) - Azide and BSA Free [NBP2-80633]
Flow Cytometry: CD19 Antibody (1D3) - Azide and BSA Free [NBP2-80633] - Analysis using the Allophycocyanin conjugate of NBP2-24965. Staining of CD19 in BALB/c mouse splenocytes. Cells were stained with anti-CD4 PE this antibody and either 1 ug of isotype control antibody (left) or 1 ug of anti-CD19 APC (right).Applications for CD19 Antibody (1D3) - Azide and BSA Free
Application
Recommended Usage
Flow Cytometry
0.25 ug/10^6 cells
Immunoprecipitation
reported in scientific literature (PMID 8566073)
In vivo assay
reported in scientific literature (PMID 8566073)
Formulation, Preparation, and Storage
Purification
Protein G purified
Formulation
PBS
Format
Azide and BSA Free
Preservative
No Preservative
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20C. Avoid freeze-thaw cycles.
Background: CD19
Considering the role of CD19 in BCR signaling and its expression in development from pre-B cells through plasma cells, it is understandable that CD19 dysfunction and abnormal expression is associated with numerous B cell malignancies and autoimmune disorders (1-5). CD19 expression is typically observed at relatively normal levels in B cell acute lymphoblastic leukemia (B-ALL) and chronic lymphoblastic leukemia (CLL) but is often reduced other types of lymphoma including diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) (1,2). On the other hand, CD19 expression is typically increased in autoimmune disorders such as systemic sclerosis (SSc) and multiple sclerosis (MS) as modeled by experimental autoimmune encephalomyelitis (EAE) (2). CD19 has become a therapeutic molecular target for the treatment of B cell lymphomas and autoimmune disorders using monoclonal antibodies (mAbs), bi-specific T cell engaging (BiTE) antibodies, and CD19-specific chimeric antigen receptor (CAR) T cells (1,2,4-6). Although anti-CD19 CAR T cell therapy has become the standard for the treatment of B cell malignancies, patients may experience relapse due to resistance mechanisms (6). Strategies to improve efficacy and limit relapse include combination of CAR T cell therapy with immune checkpoint inhibitors like anti-PD-1 (4,6).
References
1. Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1(1):36. https://doi.org/10.1186/2162-3619-1-36
2. Li X, Ding Y, Zi M, et al. CD19, from bench to bedside. Immunol Lett. 2017;183:86-95. https://doi.org/10.1016/j.imlet.2017.01.010
3. Wentink MWJ, van Zelm MC, van Dongen JJM, Warnatz K, van der Burg M. Deficiencies in the CD19 complex. Clin Immunol. 2018;195:82-87. https://doi.org/10.1016/j.clim.2018.07.017
4. Frigault MJ, Maus MV. State of the art in CAR T cell therapy for CD19+ B cell malignancies. J Clin Invest. 2020;130(4):1586-1594. https://doi.org/10.1172/JCI129208
5. Penack O, Koenecke C. Complications after CD19+ CAR T-Cell Therapy. Cancers (Basel). 2020;12(11):3445. https://doi.org/10.3390/cancers12113445
6. Bouziana S, Bouzianas D. Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy. Crit Rev Oncol Hematol. 2021;157:103096. https://doi.org/10.1016/j.critrevonc.2020.103096
Alternate Names
CD19, CVID3, Leu-12
Gene Symbol
CD19
Additional CD19 Products
Product Documents for CD19 Antibody (1D3) - Azide and BSA Free
Product Specific Notices for CD19 Antibody (1D3) - Azide and BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...